Newronika is a Milan-based medtech company pioneering adaptive deep brain stimulation (aDBS) therapy. Their αDBS platform received CE Mark certification in July 2026, advancing adaptive DBS as a new standard of care for Parkinson's disease and other movement disorders.
Company Info
Funding & Investor Relations
Pre-IPO; no announced timeline
Upcoming Milestones & Key Dates
EU commercial launch of αDBS platform
FDA IDE filing
Clinical Development Pipeline
Recent News
/PRNewswire/ -- Newronika S.p.A., the Milan-based medtech company redefining deep brain stimulation therapy, has received CE Mark certification for the latest...
Leadership Team
CEO & Co-Founder
Chief Medical Officer
VP Engineering
Careers & Job Openings